Cognitive Changes following Bilateral Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease: A Meta-Analysis

Table 3

Meta-analysis results of pretreatment parameters for STN DBS versus control.

Item	statistic	Mean and 95% CI (fixed-effect model)	Mean and 95% CI (randomized-effect model)
Age	43%	−1.54 (−2.67, −0.41)	−1.77 (−3.33, −0.21)
Duration of disease (month)	81%	0.9 (0.2, 1.59)	1.23 (−0.43, 2.89)
LED (mg/day)	86%	138.5 (75.83, 202.07)	142.9 (−27.17, 312.97)
UPDRS off-med	0	2.06 (−0.12, 4.25)	2.06 (−0.12, 4.25)
UPDRS on-med	54%	−0.89 (−2.46, 0.69)	−1.01 (−3.36, 1.34)
Hoehn-Yahr off-med	0	−0.04 (−0.19, 1.11)	−0.04 (−0.19, 1.11)
Hoehn-Yahr on-med	32%	−0.08 (−0.17, 0.02)	−0.07 (−0.19, 0.05)

CI: confidence interval; LED: levodopa equivalent dose; UPDRS: unified Parkinson disease rating scale.